Alpine Immune Sciences Announces First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program ALPN-101
First Dual ICOS/CD28 Inhibitor to Enter Clinical Trials
This study will evaluate the safety and tolerability of single- and multiple-ascending intravenous and/or subcutaneous doses of ALPN-101. In addition, pharmacokinetics, pharmacodynamics, and exploratory biomarkers are being evaluated to help determine ALPN-101’s potential for the treatment of autoimmune and inflammatory diseases. The company expects data later in 2019.
“This first dosing in the initial clinical trial of ALPN-101 is an
important milestone for Alpine as we have now transitioned to a
clinical-stage development company,” stated
AIS-A01 is a randomized, placebo-controlled, blinded study in adult
healthy volunteers to evaluate the safety, tolerability,
pharmacokinetics (PK), and pharmacodynamics of single and multiple
ascending doses of ALPN-101. The trial is being conducted in
About ALPN-101
ALPN-101 is a novel Fc fusion protein of a human inducible T cell
costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD™), and a
first-in-class therapeutic simultaneously inhibiting the CD28 and
ALPN-101 was engineered using Alpine’s vIgD platform, which uses directed evolution to transform native IgSF proteins into multifunctional protein therapeutics.
About
Forward-Looking Statements
This release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are not based on
historical fact and include statements regarding our platform technology
and potential therapies, the timing of and results from clinical trials
and pre-clinical development activities, the potential efficacy, safety
profile, future development plans, addressable market, regulatory
success and commercial potential of our product candidates, the efficacy
of our clinical trial designs and our ability to successfully develop
and achieve milestones in our development programs. Forward-looking
statements generally include statements that are predictive in nature
and depend upon or refer to future events or conditions, and include
words such as “may,” “will,” “should,” “would,” “expect,” “plan,”
“intend,” and other similar expressions among others. These
forward-looking statements are based on current assumptions that involve
risks, uncertainties and other factors that may cause actual results,
events or developments to be materially different from those expressed
or implied by such forward-looking statements. These risks and
uncertainties, many of which are beyond our control, include, but are
not limited to: clinical trials may not demonstrate safety and efficacy
of any of our product candidates; our ongoing discovery and pre-clinical
efforts may not yield additional product candidates; our discovery-stage
and pre-clinical programs may not advance into the clinic or result in
approved products; any of our product candidates may fail in
development, may not receive required regulatory approvals, or may be
delayed to a point where they are not commercially viable; we may not
achieve additional milestones in our proprietary or partnered programs;
the impact of competition; adverse conditions in the general domestic
and global economic markets; as well as the other risks identified in
our filings with the
“Transmembrane Immunomodulatory Protein,” “TIP,” “Variant Ig Domain,”
“vIgD” and the Alpine logo are registered trademarks or trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20190211005346/en/
Source:
Investor Relations:
Pure Communications
Courtney Dugan,
212-257-6723
[email protected]
Media Relations:
Pure Communications
Jennifer Paganelli,
347-658-8290
[email protected]